



**PATENT**  
Attorney Docket Nos. 084/US/PCT2/US and  
00537-188002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF: :  
: **GORDON, Thomas D. et al.** :  
: APPLICATION NO.: 09/868,356 :  
: FILED: August 10, 2001 :  
: FOR: **PRENYL TRANSFERASE INHIBITORS** :  
-----

EXAMINER: **Coleman, Brenda Libby**  
ART UNIT: **1624**

Mail Stop Non-Fee Amendment  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify under 37 CFR 1.8(a) that this  
correspondence is being deposited with the United  
States Postal Service as first class mail with  
sufficient postage on the date indicated below and  
is addressed to the Assistant Commissioner of  
Patents, Washington, D.C. 20231.  
Date of Deposit: January 14, 2004

Dawn Janelle  
Dawn M. Janelle

Sir:

REPLY UNDER 37 C.F.R. §1.111


In response to the Office Action (Paper No. 11) mailed  
on July 14, 2003, the period for response there having been  
extended so as to expire on January 14, 2004 pursuant to  
Applicants' Petition for Extension of Time filed  
concurrently with this Reply, please amend the above-  
identified application as follows.

The present amendments follow the revised format  
procedure mandated in 68 Fed. Reg. 38611 published June 30,  
2003.

Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 2

**COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS**  
 (Currently amended claims showing deletions by ~~striketrough~~  
 and additions by underlining)

1 (currently amended): A compound of formula I,



(I)

wherein

$n_1$  is 0 ~~or 1~~;


X is, independently for each occurrence,  $(CHR^{11})_{n_3}(CH_2)_{n_4}Z(CH_2)_{n_5}$ ;

Z is O,  $N(R^{12})$ , S, or a bond;

$n_3$  is, independently for each occurrence, 0 or 1;

$n_4$  and  $n_5$  each is, independently for each occurrence, 0, 1, 2, or 3;

Y is, independently for each occurrence, CO,  $CH_2$ , CS, or a bond;



$R^2$ ,  $R^{11}$ , and  $R^{12}$  each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl and

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 3

aryl, wherein said optionally substituted moiety is optionally substituted with one or more of  $R^8$  or  $R^{30}$ ;  $R^3$  is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{2-6})$ alkynyl,  $(C_{3-6})$ cycloalkyl,  $(C_{3-6})$ cycloalkyl $(C_{1-6})$ alkyl,  $(C_{5-7})$ cycloalkenyl,  $(C_{5-7})$ cycloalkenyl $(C_{1-6})$ alkyl, aryl, aryl $(C_{1-6})$ alkyl, heterocyclyl, and heterocyclyl $(C_{1-6})$ alkyl, wherein said optionally substituted moiety is optionally substituted with one or more  $R^{30}$ ;

$R^4$  and  $R^5$  each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{3-6})$ cycloalkyl, aryl, and heterocyclyl, wherein said optionally substituted moiety is optionally substituted with one or more  $R^{30}$ , wherein each said substituent is independently selected, or  $R^4$  and  $R^5$  can be taken together with the carbons to which they are attached to form aryl;

$R^6$  is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{3-6})$ cycloalkyl,  $(C_{3-6})$ cycloalkyl $(C_{1-6})$ alkyl,  $(C_{5-7})$ cycloalkenyl,  $(C_{5-7})$ cycloalkenyl $(C_{1-6})$ alkyl, aryl, aryl $(C_{1-6})$ alkyl, heterocyclyl, and heterocyclyl $(C_{1-6})$ alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH,  $(C_{1-6})$ alkyl,  $(C_{1-6})$ alkoxy,  $-N(R^8R^9)$ ,  $-COOH$ ,  $-CON(R^8R^9)$ , and halo, where  $R^8$  and  $R^9$  each is, independently for each occurrence, H,  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{2-6})$ alkynyl, aryl, or aryl $(C_{1-6})$ alkyl;

$R^7$  is, independently for each occurrence, H, =O, =S, or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{3-6})$ cycloalkyl,

Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 4


(C<sub>3-6</sub>)cycloalkyl(C<sub>1-6</sub>)alkyl, (C<sub>5-7</sub>)cycloalkenyl, (C<sub>5-7</sub>)cycloalkenyl(C<sub>1-6</sub>)alkyl, aryl, aryl(C<sub>1-6</sub>)alkyl, heterocyclyl, and heterocyclyl(C<sub>1-6</sub>)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C<sub>1-6</sub>)alkyl, (C<sub>1-6</sub>)alkoxy, -N(R<sup>8</sup>R<sup>9</sup>), -COOH, -CON(R<sup>8</sup>R<sup>9</sup>), and halo;

R<sup>10</sup> is C;

~~or when n1 = 0, R<sup>6</sup> and R<sup>7</sup> can be taken together with the carbon atoms to which they are attached to form aryl or cyclohexyl;~~

R<sup>21</sup> is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C<sub>1-6</sub>)alkyl and aryl(C<sub>1-6</sub>)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of R<sup>8</sup> and R<sup>30</sup>;

R<sup>22</sup> is H, (C<sub>1-6</sub>)alkylthio, (C<sub>3-6</sub>)cycloalkylthio, R<sup>8</sup>-CO-, or a substituent according to the formula



R<sup>24</sup> and R<sup>25</sup> each is, independently for each occurrence, H, (C<sub>1-6</sub>)alkyl, or aryl(C<sub>1-6</sub>)alkyl;

R<sup>30</sup> is, independently for each occurrence, (C<sub>1-6</sub>)alkyl, -O-R<sup>8</sup>, -S(O)<sub>n6</sub>R<sup>8</sup>, -S(O)<sub>n7</sub>N(R<sup>8</sup>R<sup>9</sup>), -N(R<sup>8</sup>R<sup>9</sup>), -CN, -NO<sub>2</sub>,

Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 5


$-\text{CO}_2\text{R}^8$ ,  $-\text{CON}(\text{R}^8\text{R}^9)$ ,  $-\text{NCO}-\text{R}^8$ , or halogen;

$n_6$  and  $n_7$  each is, independently for each occurrence, 0, 1, or 2;


wherein said heterocyclyl is azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, or thienyl; and wherein said aryl is phenyl or naphthyl;

provided that:

either  $\text{R}^6$  is H or  $\text{R}^7$  is  $=\text{O}$ ,  $-\text{H}$ , or  $=\text{S}$  wherein when  $n_1 = 1$ ,  $\text{R}^{10}$  is C and  $\text{R}^6$  is H, then  $\text{R}^{10}$  and  $\text{R}^7$  are can be taken together




to form  $(\text{R}^7)$ ; or when  $n_1 = 1$ ,  $\text{R}^{10}$  is C, and  $\text{R}^7$  is  $=\text{O}$ ,  $-\text{H}$ , or  $=\text{S}$ , then  $\text{R}^{10}$  and  $\text{R}^6$  are can be taken together to form




Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 6

wherein  $X^1$ ,  $X^2$ , and  $X^3$  each is, independently, H, halogen,  $-\text{NO}_2$ ,  $-\text{NCO}-\text{R}^8$ ,  $-\text{CO}_2\text{R}^8$ ,  $-\text{CN}$ , or  $-\text{CON}(\text{R}^8\text{R}^9)$ ; and when  $\text{R}^1$  is  $\text{N}(\text{R}^{24}\text{R}^{25})$ , then  $n_3$  is 1,  $n_4$  and  $n_5$  each is 0, Z is a bond, and  $\text{R}^3$  and  $\text{R}^{11}$  can be taken together to form




wherein  $n_2$  is 1-6, and  $X^4$  and  $X^5$  each is, independently, H,  $(\text{C}_{1-6})$ alkyl, or aryl, or  $X^4$  and  $X^5$  can be taken together to form  $(\text{C}_{3-6})$ cycloalkyl; or a pharmaceutically acceptable salt thereof.

2 (original): A compound according to claim 1, wherein:




3 (withdrawn): A compound according to claim 2, wherein:



Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 7

or a pharmaceutically acceptable salt thereof.

4 (withdrawn): A compound according to claim 2,  
 wherein:



n<sub>3</sub>, n<sub>4</sub>, and n<sub>5</sub> each is 0;


Z is a bond;

Y is, independently for each occurrence, CO or CS; and

n<sub>1</sub> is 0;


or a pharmaceutically acceptable salt thereof.

5 (original): A compound according to claim 2,  
 wherein:



R<sup>6</sup> is H;

n<sub>1</sub> is 1;



R<sup>7</sup> and R<sup>10</sup> are taken together to form

n<sub>3</sub> is 1 and R<sup>11</sup> is H;

Z is O or a bond;

n<sub>5</sub> is 0; and

Y is CO, CH<sub>2</sub>, or a bond;

or a pharmaceutically acceptable salt thereof.

Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 8

6 (withdrawn): A compound according to claim 2,  
 wherein:

$R^1$  is  $N(R^{24}R^{25})$ ;

$n_1$  is 0;


$n_3$  is 1;

$n_4$  is 0;

$n_5$  is 0;


Y is CO or CS;

Z is a bond; and



$R^3$  and  $R^{11}$  are taken together to form ,  
 or a pharmaceutically acceptable salt thereof.


7 (original): A compound according to claim 2,  
 wherein:



$R^1$  is ;

$R^7$  is H or =O;

$n_1$  is 1;



$R^6$  and  $R^{10}$  are taken together to form ;

$n_3$  is 1 and  $R^{11}$  is H;

$n_5$  is 0;

Y is CO or  $CH_2$ ; and

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 9

Z is O or a bond;

or a pharmaceutically acceptable salt thereof.

8 (withdrawn): A compound according to claim 3, wherein said compound is

8-butyl-7-(3-(imidazol-5-yl)-1-oxopropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-2-(2-hydroxyphenyl)-7-(imidazol-4-yl-propyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-7-(4-imidazolylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(imidazol-4-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(1-oxo-2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((1H-imidazol-4-yl)methyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((4-imidazolyl)carbonyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(1-(4-cyanophenylmethyl)-imidazol-5-yl)methyl-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

5-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 10

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

5-butyl-7-(2-(1H-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-(phenylmethoxy)-phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or

2-(2-butoxyphenyl)-7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or a pharmaceutically acceptable salt thereof.

9 (currently amended): A compound according to claim 5, wherein said compound is

1,2-dihydro-1-((1H-imidazol-4-yl)methyl)-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-cChloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 11

10-~~b~~Bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; ~~or~~

or a pharmaceutically acceptable salt thereof.

10 (currently amended): A compound according to claim 9, wherein said compound is

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-~~c~~Chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-~~b~~Bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

or a pharmaceutically acceptable salt thereof.

11 (withdrawn): A compound according to claim 6, wherein said compound is

7-(2-amino-1-oxo-3-thiopropyl)-8-(mercaptoethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide;

or a pharmaceutically acceptable salt thereof.

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 12



12 (original): A compound according to claim 7,  
wherein said compound is

5-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-  
ethyl)-5,6-dihydro-2-phenyl-1H-imidazo[1,2-  
a][1,4]benzodiazepine;  
or a pharmaceutically acceptable salt thereof.







13 (original): A compound according to claim 2  
wherein said compound is

1,2-dihydro-1-(2-(imidazol-1-yl)-1-oxoethyl)-4-(2-  
methoxyphenyl) imidazo[1,2a][1,4]benzodiazepine;  
1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-3-yl)-1-  
oxoethyl) imidazo[1,2a][1,4]benzodiazepine; or  
1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-4-yl)-1-  
oxoethyl) imidazo[1,2a][1,4]benzodiazepine;  
or a pharmaceutically acceptable salt thereof.


14 (original): A compound according to claim 2,  
wherein said compound is








Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 13









Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 14








Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 15



Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 16



Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 17



or a pharmaceutically acceptable salt thereof.

15 (currently amended): A pharmaceutical composition for use in treating a disease selected from the group consisting of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer,

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 18


epidermal cancer and hematopoietic cancer, comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

16 (currently amended): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said disease is selected from the group consisting of ~~fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis,~~ breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer, and hematopoietic cancer, ~~and hepatitis delta virus infection.~~






17 (canceled)

18 (canceled)





19 (original): A compound according to claim 2, wherein said compound is



Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 19



Inventor : Gordon et al.  
 Serial No. : 09/868,356  
 Filed : August 10, 2001  
 Page : 20



or a pharmaceutically acceptable salt thereof.

--20 (new): A pharmaceutical composition for use in treating a disease selected from the group consisting of fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis and hepatitis delta virus infection comprising an

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 21

effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

21 (new): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said disease is selected from the group consisting of fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis and hepatitis delta virus infection.--